Model Selection and Endpoint Planning Support
Instead of starting with an available model, we begin with what must be clarified before moving into dog or cat studies, then work backward to define the evaluation strategy.
KGAH-ONE organizes disease biology, mechanism of action, model fit, endpoints, biomarkers, candidate comparison, dose, timing, and Go / No-Go criteria as one decision-oriented evaluation pathway.
KGAH-ONE starts with the development question, not a predetermined model.
Even when a model has already been selected, study results may be difficult to use if the mechanism, intervention timing, comparison conditions, or readouts do not match the development question.
KGAH-ONE first clarifies what must be demonstrated before moving into dog or cat studies, then connects the program with suitable model, pathology, and analytical capabilities through specialized partners such as SMC Laboratories where appropriate.
Which uncertainty must be reduced before moving into dog or cat studies?
We identify which factors—candidate, mechanism, disease state, dose, timing, endpoint, or biomarker—will determine the next development decision.
Design the model and readouts from the evidence needed for the decision—not the other way around.
The goal is to interpret not only whether a candidate worked, but why it worked, why it did not, and what should be changed next.
What can happen when model selection is not decision-oriented
A numerical difference may be observed without explaining mechanism, the team may still be unable to select the candidate, dose, or endpoint for dog or cat studies, or Go / No-Go criteria may be added only after the study is complete. The most costly outcome is not an ambiguous result—it is a result that cannot explain why it was ambiguous.
Five elements to organize before study design
Model fit cannot be assessed in isolation. Disease biology, endpoints, biomarkers, and decision criteria should be designed as one connected pathway.
Disease Biology
Define the disease state, progression stage, tissue changes, inflammation, fibrosis, or immune biology that must be represented.
Model Fit
Clarify what the model reproduces—and does not reproduce—in relation to mechanism, intervention timing, and target pathology.
Endpoint
Combine functional, pathological, imaging, molecular, and immune readouts according to the development decision.
Biomarker
Consider indicators for mechanism confirmation, response interpretation, and translation into future dog or cat studies.
Decision Criteria
Set candidate, dose, additional validation, and Go / No-Go criteria before the study begins.
Translate a development question into an executable evaluation system
KGAH-ONE organizes the question and decision logic, then connects them with the execution capabilities of specialized partners.
Development Question
What must be clarified before moving into dog or cat studies or the next development stage?
KGAH-ONE
MoA, model, endpoint, biomarker, candidate comparison, Go / No-Go, and partner design.
Specialized Partners
Disease models, pathology, tissue analysis, molecular and immune readouts, and quantitative analysis.
Development Question
Define the primary decision: candidate selection, mechanism, dose, timing, comparison, or next-study readiness.
Evidence Package
Organize the required combination of functional, pathological, molecular, immune, and imaging evidence.
Model and Analysis Plan
Design the model, groups, dose, intervention timing, comparator, samples, and readouts.
Next Development Decision
Connect the results with Go / No-Go, candidate ranking, condition changes, additional validation, or dog and cat study planning.
Representative model-selection matrix
These examples are based on information that specialized partners have approved for external use. Actual plans should be tailored to mechanism, target species, development stage, and the endpoints expected in future dog or cat studies.
| Disease Area | Representative Model | Pathology / Use | Representative Endpoints | Development Decision |
|---|---|---|---|---|
| CKD / Tubulointerstitial Injury | Adenine-induced CKD | Tubular injury, interstitial inflammation, renal fibrosis, and impaired renal function | BUN, plasma creatinine, GFR, uACR, PAS, Sirius Red-positive area, α-SMA, collagen, inflammatory markers | Renal protection, reduced tubular injury, anti-inflammatory and anti-fibrotic activity, dose response, Go / No-Go |
| Renal Fibrosis | UUO | Rapidly progressing tubulointerstitial fibrosis | Sirius Red-positive area, α-SMA, hydroxyproline, collagen expression, macrophage infiltration | Anti-fibrotic activity, fibroblast activation, inflammation, and mechanism |
| ADPKD / PKD | pcy mouse | Progressive cyst formation, renal enlargement, tubular injury, and impaired renal function | Cystic area / cystic index, kidney-to-body weight ratio, urine NGAL / creatinine, BUN, fibrosis area | Suppression of cyst progression and renal enlargement, standard-of-care comparison, candidate ranking |
| Pulmonary Fibrosis / ILD | Bleomycin pulmonary fibrosis / SSc-ILD | Alveolar injury, inflammation, fibrosis, and impaired lung function | Ashcroft score, Sirius Red / Masson, hydroxyproline, α-SMA, BALF, micro-CT, Rrs / Ers / Crs | Anti-fibrotic activity, reduced lung inflammation, tissue and lung-function improvement, comparator assessment |
| Oncology | Xenograft | Human tumor-cell growth and drug response | Tumor volume, tumor weight, survival, IHC, proliferation / apoptosis markers, PK / PD biomarkers | Direct anti-tumor activity, dose response, combination effect, and pharmacodynamic action |
| MASH-associated HCC / IO | STAM™-IO | Spontaneous HCC in a MASH background, including an ICI-low-response tumor immune environment | Tumor number / burden, survival, H&E, IHC, CD8 / macrophage infiltration, PD-L1, cytokines | Anti-tumor activity, immune response, immune-checkpoint inhibitors, combination therapy, and tumor microenvironment |
These are representative examples and do not constitute a universal recommendation for any specific model. Feasibility, group design, animals, study conditions, and analytical endpoints should be confirmed individually.
Outputs that should come from evaluation planning
The objective is not simply to produce a study plan, but to create a state in which the development team can make the next decision.
Candidate Prioritization
Organize candidate differences, alignment with mechanism, and the rationale for moving into the next stage.
Dose and Intervention Timing
Evaluate dose response, preventive or therapeutic intervention, and the conditions to carry forward.
Integrated Readouts
Combine function, pathology, molecular, immune, and imaging endpoints to interpret both effect and reason.
Go / No-Go and Next Step
Clarify the conditions for continuation, modification, additional validation, termination, or dog and cat study preparation.
Mouse studies are not a substitute for dog or cat studies.
They are a preceding step for making later dog or cat studies more interpretable by clarifying candidates, mechanism, dose, endpoints, biomarkers, and Go / No-Go criteria.
Representative public track record of a specialized partner
These are externally usable performance statements from SMC Laboratories, a specialized partner that may be engaged depending on the development question. KGAH-ONE leads problem definition and coordination design.
Before selecting a model, organize the evidence needed for the next decision.
Tell us the target disease, modality, mechanism of action, candidate stage, expected dog or cat study, and current development question. KGAH-ONE can help organize the model, endpoints, biomarkers, pathology, analytical strategy, and specialized partner pathway.
KGAH-ONE is an Animal Health intelligence and partner coordination platform of Kawasaki Global Animal Health, Inc. Specialized nonclinical evaluation and scientific support may be provided by partners such as SMC Laboratories, depending on the development question.